Elif Alyanak supports clients with evidence-based research and analysis that spans a variety of healthcare sectors and stakeholders.

With a background in health policy and vaccine research, she applies her skills in comparative effectiveness and recommendation development to a broad range of client projects.

Before joining Avalere, Elif held a variety of positions researching infectious disease prevention and vaccination at the Centers for Disease Control and Prevention. Formerly an Oak Ridge Institute for Science and Education fellow and senior analyst/epidemiologist within the National Center for Immunization and Respiratory Diseases, she supported many federal government vaccination studies and policy research. Additionally, Elif managed systematic reviews and meta-analyses and synthesized clinical vaccine literature while directly supporting the Advisory Committee on Immunization Practices.

Elif has a BS in biology from the Georgia Institute of Technology and an MPH in health policy and management from Georgia State University. She is currently pursuing a DrPH in health policy from George Washington University.

Authored Content


In the fifth installment of our Respiratory Syncytial Virus (RSV) prevention series, Avalere experts discuss updates to the RSV prevention landscape, including newly approved products and recent Advisory Committee on Immunization Practices (ACIP) meeting discussions.

At its June meeting, ACIP reviewed data on several currently marketed and novel immunizations, highlighting the committee's focus on cost, accessibility, and equity.

Updated Avalere analysis finds MA beneficiaries with chronic conditions had fewer inpatient stays and ED visits than FFS Medicare beneficiaries.

The proposed vaccine definition would have a significant market impact on novel immunizations such as preventive immunoglobulins and therapeutic vaccines.

Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.

Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.

Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.

Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.

Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.

Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.

Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.

Numerous novel respiratory syncytial virus (RSV) preventive products, including vaccines and monoclonal antibodies (mAbs), are in late-stage clinical development. Consequently, the RSV prevention landscape is expected to transform in the coming years. Adequate preparation to incorporate the use of these new tools should consider the regulatory and recommendation pathways and their implications for coverage and reimbursement.

On February 2, 2022, President Biden announced a revitalization of the Obama-era Cancer Moonshot Initiative, including updated goals to reduce cancer deaths by at least 50% over the next 25 years and improve the experience of cancer survivorship for patients and their families.